{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:30:43Z","timestamp":1789169443262,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To describe trends and factors associated with medication administration for opioid use disorder (OUD) and retention in treatment among pregnant women with OUD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>This is a retrospective, nationwide, cross-sectional analysis of treatment episodes for primary OUD among pregnant women from 2013 to 2017. The primary outcome was initiation of methadone, buprenorphine, or naltrexone. Secondary outcomes were retention in treatment defined as length of treatment episode lasting six months or greater, and completion of treatment. Descriptive statistics and logistic regression were applied to describe trends in, and identify factors associated with the outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>There were 42,239 treatment episodes for primary OUD among pregnant women who reported using heroin (65.0%, 27,459), synthetic opioid (33.2%, 14,034), or nonprescribed methadone (1.8%, 746) between 2013 and 2017. Medications for OUD were administered in 47.4% (20,013) of episodes. Retention in treatment occurred in 16.6% of episodes without medications for OUD, and 37.8% of episodes with medications for OUD (<jats:italic toggle=\"yes\">P<\/jats:italic>=.01). The rate of medication administration for OUD increased from 41.0% in 2013 to 52.0% in 2017; however, retention rates declined from 39.0% to 33.0% among treatment episodes with medication for OUD. History of at least one prior treatment episode was associated with both administration of medications for OUD and retention in treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>In spite of current guidelines, most treatment episodes for OUD during pregnancy did not involve administration of medications for OUD. Although administration of medications for OUD has improved over time, retention in treatment is lagging. These findings highlight gaps in the U.S. addiction care system.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004307","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T23:01:00Z","timestamp":1615503660000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Predictors of Initiation of Medication for Opioid Use Disorder and Retention in Treatment Among U.S. Pregnant Women, 2013\u20132017"],"prefix":"10.1097","volume":"137","author":[{"given":"Max Jordan","family":"Nguemeni Tiako","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Culhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"South","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary F.","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2014.07.007","article-title":"Recent trends in treatment admissions for prescription opioid abuse during pregnancy","volume":"48","author":"Martin","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"799","DOI":"10.15585\/mmwr.mm6531a2","article-title":"Incidence of neonatal abstinence syndrome - 28 states, 1999-2013","volume":"65","author":"Ko","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm6801a2","article-title":"Evaluation of state-mandated reporting of neonatal abstinence syndrome \u2014 six states, 2013\u20132017","volume":"68","author":"Jilani","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20250430","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clp.2013.05.015","article-title":"Chronic opioid use during pregnancy: maternal and fetal implications","volume":"40","author":"Stanhope","year":"2013","journal-title":"Clin Perinatol"},{"key":"R5-20250430","first-page":"e81","article-title":"Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists","volume":"130","year":"2017"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/aje\/kwu190","article-title":"Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis","volume":"180","author":"Brogly","year":"2014","journal-title":"Am J Epidemiol"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/jmwh.13019","article-title":"Maternity care for pregnant women with opioid use disorder: a review","volume":"64","author":"Rizk","year":"2019","journal-title":"J Midwifery Womens Heal"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/AOG.0000000000003231","article-title":"Medication-assisted treatment use among pregnant women with opioid use disorder","volume":"133","author":"Krans","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R10-20250430","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/08897077.2018.1488336","article-title":"Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states","volume":"40","author":"Patrick","year":"2019","journal-title":"Subst Abus"},{"key":"R11-20250430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jsat.2017.01.011","article-title":"Substance use, treatment, and demographic characteristics of pregnant women entering treatment for opioid use disorder differ by United States census region","volume":"76","author":"Hand","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"R12-20250430","first-page":"13","article-title":"To battle the opioid overdose epidemic, deploy the cascade of care model","author":"Williams","year":"2017","journal-title":"Heal Aff Blog"},{"key":"R13-20250430","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","article-title":"Developing an opioid use disorder treatment cascade: a review of quality measures","volume":"91","author":"Williams","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a Cascade of Care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R16-20250430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"e205734","DOI":"10.1001\/jamanetworkopen.2020.5734","article-title":"Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts","volume":"3","author":"Schiff","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R18-20250430","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0304-4076(80)90007-X","article-title":"Partial observability in bivariate probit models","volume":"12","author":"Poirier","year":"1980","journal-title":"J Econom"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/COGRM.1000223","article-title":"Obstetrician-gynecologists' referral practices for substance use during pregnancy","volume":"4","author":"Coleman-Cowger","year":"2018","journal-title":"Clin Obstet Gynecol Reprod Med"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"e2013456","DOI":"10.1001\/jamanetworkopen.2020.13456","article-title":"Association of pregnancy and insurance status with treatment access for opioid use disorder","volume":"3","author":"Patrick","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R22-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03630242.2019.1610829","article-title":"Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment","volume":"60","author":"Jancaitis","year":"2020","journal-title":"Women Heal"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1377\/hlthaff.2016.1241","article-title":"Women in the United States experience high rates of coverage churn in months before and after childbirth","volume":"36","author":"Daw","year":"2017","journal-title":"Health Aff"},{"key":"R24-20250430","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2012.3951","article-title":"Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009","volume":"307","author":"Patrick","year":"2012","journal-title":"JAMA"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2017.12.001","article-title":"Predictors of treatment retention in postpartum women prescribed buprenorphine during pregnancy","volume":"86","author":"O'Connor","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"R26-20250430","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/pds.4647","article-title":"Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States","volume":"28","author":"Lo-Ciganic","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R27-20250430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0035-1556740","article-title":"Prescription opioids in pregnancy and birth outcomes: a review of the literature","volume":"4","author":"Yazdy","year":"2015","journal-title":"J Pediatr Genet"},{"key":"R28-20250430","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10995-019-02839-9","article-title":"One-year postpartum mental health outcomes of mothers of infants with neonatal abstinence syndrome","volume":"24","author":"Corr","year":"2020","journal-title":"Matern Child Health J"},{"key":"R29-20250430","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ajog.2019.02.056","article-title":"Maternal self-harm deaths: an unrecognized and preventable outcome","volume":"221","author":"Mangla","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"R30-20250430","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/AOG.0000000000001695","article-title":"Maternal deaths from suicide and overdose in Colorado, 2004-2012","volume":"128","author":"Metz","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R31-20250430","doi-asserted-by":"crossref","first-page":"489.e1","DOI":"10.1016\/j.ajog.2019.05.045","article-title":"Maternal drug-related death and suicide are leading causes of postpartum death in California","volume":"221","author":"Goldman-Mellor","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"R32-20250430","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40352-019-0089-6","article-title":"Probation clients' barriers to access and use of opioid use disorder medications","volume":"7","author":"Reichert","year":"2019","journal-title":"Heal Justice"},{"key":"R33-20250430","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1111\/add.15030","article-title":"Opioid use disorder incidence and treatment among incarcerated pregnant people in the U.S.: results from a national surveillance study","volume":"115","author":"Sufrin","year":"2020","journal-title":"Addiction"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:42:20Z","timestamp":1746081740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004307","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"2020-10-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}